ISU Abxis Co., Ltd. (KOSDAQ:086890)
3,495.00
+325.00 (10.25%)
At close: Jun 29, 2026
ISU Abxis Market Cap
ISU Abxis has a market cap or net worth of 142.51 billion as of June 29, 2026. Its market cap has decreased by -23.90% in one year.
Market Cap
142.51B
Enterprise Value
144.74B
Revenue
58.94B
Ranking
n/a
PE Ratio
n/a
Stock Price
3,495.00
Market Cap Chart
Since February 3, 2009, ISU Abxis's market cap has increased from 55.97B to 142.51B, an increase of 154.63%. That is a compound annual growth rate of 5.51%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Jun 29, 2026 | 142.51B | -30.73% |
| Dec 30, 2025 | 205.73B | 28.77% |
| Dec 30, 2024 | 159.77B | -23.70% |
| Dec 28, 2023 | 209.40B | 9.75% |
| Dec 29, 2022 | 190.80B | -34.58% |
| Dec 30, 2021 | 291.68B | 43.53% |
| Dec 30, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 30, 2019 | Upgrade Pro | Upgrade Pro |
| Dec 28, 2018 | Upgrade Pro | Upgrade Pro |
| Dec 28, 2017 | Upgrade Pro | Upgrade Pro |
| Dec 29, 2016 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Kanaph Therapeutics | 183.96B |
| NIBEC | 179.16B |
| Ensol Biosciences | 167.70B |
| Y-Biologics | 165.59B |
| Genome & Company | 161.29B |
| Bio Solution | 152.25B |
| Prestige Biologics | 151.23B |
| ViGenCell | 123.61B |